Mild cognitive impairment

被引：92

作者：

Chertkow, H

机构：

[1] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada

[2] Sir Mortimer B Davis Jewish Hosp, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada

[3] Sir Mortimer B Davis Jewish Hosp, Dept Clin Neurosci, Montreal, PQ H3T 1E2, Canada

[4] Sir Mortimer B Davis Jewish Hosp, Div Geriatr Med, Dept Med, Montreal, PQ H3T 1E2, Canada

[5] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada

[6] Univ Geriatr Inst Montreal, Montreal, PQ, Canada

来源：

CURRENT OPINION IN NEUROLOGY | 2002年 / 15卷 / 04期

关键词：

D O I：

10.1097/00019052-200208000-00001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Mild cognitive impairment is an emerging term that encompasses the clinical state between elderly normal cognition and dementia. Controversy surrounds its characterization, implementation, and definition. Mild cognitive impairment is now the focus of natural history studies, biomarker studies, along with Alzheimer's disease prevention studies. The mild cognitive impairment stage may be the optimum stage at which to intervene with preventive therapies. Depending on the cohort source and definition, between 19 and 50% of mild cognitive impairment individuals progress to dementia (usually Alzheimer's disease) over 3 years. Despite controversy, progress has been achieved in defining risk factors for progression from mild cognitive impairment to dementia. New treatments to prevent development of Alzheimer's disease are targeting mild cognitive impairment as a treatment group and neurologists will increasingly be called upon to make this diagnosis.

引用

页码：401 / 407

页数：7

共 67 条

[1] Preclinical prediction of AD using neuropsychological tests [J].